Press release
Mobius Care Receives Funding from Crohn's & Colitis Foundation to Advance AI-Powered Precision Medicine for Inflammatory Bowel Disease (IBD)
CLEVELAND, OH - February 13, 2025 - Mobius Care, a Cleveland Clinic-founded company that is pioneering a new approach to precision medicine for patients with Inflammatory Bowel Disease (IBD), today announced it has received funding from the Crohn's & Colitis Foundation. The Foundation is a non-profit organization committed to finding cures for Crohn's disease and ulcerative colitis.The funding will primarily be used to advance Mobius Care's innovative H&E image-based predictive biomarker, which uses artificial intelligence (AI) to predict patients' responses to existing IBD therapies from standard-of-care H&E images. This biomarker is the first of its kind and offers the potential for a new tool for clinicians to personalize treatment plans for IBD patients.
"The Crohn's and Colitis Foundation has been a valuable partner, and we greatly appreciate their early support of our efforts," said Thaddeus Stappenbeck, MD, PhD, Chair of the Department of Inflammation and Immunity at Cleveland Clinic and founder of Mobius Care. "The Foundation recognizes the complexity of treating IBD, which affects 1 in 100 Americans. While precision medicine has made strides in other areas, progress in IBD has remained limited, with current therapies showing response rates as low as 50%. This uncertainty in treatment effectiveness highlights a pressing unmet need within the field. We look forward to building on our collaboration with The Foundation as Mobius works to advance precision diagnostics and develop innovative therapies that can transform the way IBD is treated and significantly improve patient outcomes."
"IBD Ventures is excited to support Mobius, which is pioneering transformative technology that addresses critical unmet needs of IBD patients," said Andrés Hurtado-Lorenzo, PhD, Senior Vice President of Translational Research and IBD Ventures at the Crohn's & Colitis Foundation. "Currently, the patient journey in IBD lacks a systematic approach. Patients often cycle through various treatments - from steroids to different biologics and small molecules - without a clear way to predict which will be most effective. This digital pathology test has the potential to bring precision medicine to IBD care."
Cristina Larkin, CEO of Mobius Care, stated, "Our focus has been on providing better solutions for patients suffering from IBD. Precision IBD has been a goal for both patients and healthcare providers, and we are excited about developing AI-supported solutions to guide the clinical selection of IBD therapeutics. We believe Mobius Care is prepared to be the first to offer a true precision medicine approach to IBD, and we are thrilled about our biomarkers and the expanding pipeline of therapeutics we are creating."
Mobius Care
10000 Cedar Ave, GCIC -10
Cleveland,OH 44106
Mobius Care is a precision medicine company focused on developing AI-powered biomarkers and therapeutics for Inflammatory Bowel Disease (IBD). The company's mission is to empower healthcare providers and patients to choose the most effective treatments based on individual response predictions. In 2021, Dr. Stappenbeck and his team published groundbreaking research in Inflammatory Bowel Diseases showing that epithelial cell biomarkers could predict patient response to biological therapies for Crohn's disease. Mobius Care is also focused on developing new markers and therapeutics aimed at promoting mucosal healing-an often overlooked but essential aspect of IBD treatment.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Mobius Care Receives Funding from Crohn's & Colitis Foundation to Advance AI-Powered Precision Medicine for Inflammatory Bowel Disease (IBD) here
News-ID: 3867838 • Views: …
More Releases for IBD
Ace Therapeutics Unveils Imaging Services for Precise Characterization of IBD An …
Ace Therapeutics launched its translational imaging services specifically designed to accurately characterize Inflammatory Bowel Disease (IBD) animal models.
New York, USA - May 28, 2025 - Ace Therapeutics, a leader in preclinical research solutions, launched its translational imaging solutions specifically designed to accurately characterize Inflammatory Bowel Disease (IBD) animal models. This breakthrough offering empowers researchers with high-resolution, quantitative data to enhance drug development and mechanistic studies.
Image: https://www.getnews.info/uploads/3c0755ac659fa5075e809ffd1b893496.jpg
Imaging techniques play a crucial…
Inflammatory Bowel Disease (IBD) Market Size, Growth Insights, and Future Trends
Inflammatory Bowel Disease (IBD) continues to pose significant challenges for individuals and healthcare systems worldwide. With its increasing prevalence, the demand for effective treatments is driving market growth. The IBD treatment market is projected to grow from USD 19.91 billion in 2023 to USD 33.19 billion by 2032, reflecting a compound annual growth rate (CAGR) of 5.5% during the forecast period.
Download Statistical Data: https://www.towardshealthcare.com/download-statistics/5149
Key Market Highlights
• Crohn's Disease Dominates: Crohn's disease…
Canada Inflammatory Bowel Disease (IBD) Market Size & Growth Analysis Report, 20 …
The Canada IBD market is estimated to grow significantly at a CAGR of around 5.2% during the forecast period. Rising prevalence and incidence of IBD across the country is the major driving factor for the market. Canada has among the highest reported prevalence and incidence rates of IBD across the globe. As per CCC, in 2018, nearly 270,000 Canadians were living with IBD, of which 135,000 individuals with Crohn’s disease,…
Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031
Visiongain has published a new report on Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031: Forecasts by Drug Class (Biologics, Aminosalicylates, Corticosteroids, Antibiotics, Immunomodulators, Others), by Indication (Crohn’s Disease, Ulcerative Colitis), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) AND Regional and Leading National Market Analysis PLUS Analysis of Leading IBD Drug Companies AND COVID-19 Recovery Scenarios.
Global Inflammatory Bowel Disease (IBD) drugs market was valued at US$ US$xx…
US Inflammatory Bowel Disease (IBD) Therapeutics Market Research and Forecast 20 …
The US IBD therapeutics market is estimated to grow significantly at a CAGR of around 4.7% during the forecast period. The factors such as the significant prevalence of IBD such as Crohn’s disease and ulcerative colitis across the country contributing to the market growth. As per the Centers for Disease Control and Prevention (CDC), the prevalence of Crohn’s disease and ulcerative colitis in the US was 201 and 238 per…
Global Inflammatory Bowel Disease (IBD) Therapeutics Market, Share, Trends & For …
The global IBD therapeutics market is estimated to grow significantly at a CAGR of around 5.0% during the forecast period. The rise in the number of IBD such as Crohn's disease and ulcerative colitis is augmenting the growth of the global IBD therapeutics market. The increasing prevalence of IBD results in the need for research for the treatment of IBD and innovations in healthcare systems to manage this complex and…